Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| cDLQI (Children's DLQI)× | MelasQoL (Melasma elukvaliteedi skaala)× | |
|---|---|---|
| Valdkond | Dermatoloogia | Dermatoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1995 | 2006 |
| Looja≠ | Lewis-Jones MS, Finlay AY | Cestari TF, Hexsel D |
| Tüüp≠ | Self-report (parent or child proxy) | Self-report |
| Algallikas≠ | Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949. DOI ↗ | Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20. link ↗ |
| Rööpnimetused≠ | cDLQI, Pediatric DLQI | Melasma-QoL |
| Seotud | 3 | 3 |
| Kokkuvõte≠ | The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice. | MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes. |
| ScholarGateAndmestik ↗ |
|
|